Mallinckrodt explores sale of generic drugs business, Reuters sources say

Mallinckrodt is exploring a sale of its generic drug unit, in a deal that could fetch as much as $2 billion, Reuters reports.

from Mergers and Acquisitions http://ift.tt/2rC0bru